CN116113402A - 帕金森病的运动并发症治疗药 - Google Patents

帕金森病的运动并发症治疗药 Download PDF

Info

Publication number
CN116113402A
CN116113402A CN202180053119.3A CN202180053119A CN116113402A CN 116113402 A CN116113402 A CN 116113402A CN 202180053119 A CN202180053119 A CN 202180053119A CN 116113402 A CN116113402 A CN 116113402A
Authority
CN
China
Prior art keywords
tandospirone
pharmaceutically acceptable
acceptable salt
levodopa
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180053119.3A
Other languages
English (en)
Chinese (zh)
Inventor
栗田光将
池田友纪
中塔充宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of CN116113402A publication Critical patent/CN116113402A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180053119.3A 2020-08-31 2021-08-30 帕金森病的运动并发症治疗药 Pending CN116113402A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020145967 2020-08-31
JP2020-145967 2020-08-31
PCT/JP2021/031722 WO2022045336A1 (ja) 2020-08-31 2021-08-30 パーキンソン病の運動合併症治療薬

Publications (1)

Publication Number Publication Date
CN116113402A true CN116113402A (zh) 2023-05-12

Family

ID=80353469

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180053119.3A Pending CN116113402A (zh) 2020-08-31 2021-08-30 帕金森病的运动并发症治疗药

Country Status (10)

Country Link
US (2) US11628169B2 (https=)
EP (1) EP4218764A4 (https=)
JP (1) JPWO2022045336A1 (https=)
KR (1) KR20230058615A (https=)
CN (1) CN116113402A (https=)
AU (1) AU2021332775A1 (https=)
CA (1) CA3189670A1 (https=)
MX (1) MX2023002422A (https=)
TW (1) TW202227080A (https=)
WO (1) WO2022045336A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116113402A (zh) * 2020-08-31 2023-05-12 住友制药株式会社 帕金森病的运动并发症治疗药

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507303A (en) 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
JPS58126865A (ja) 1981-12-22 1983-07-28 Sumitomo Chem Co Ltd 環状イミド誘導体及びその酸付加塩
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
JPH11228414A (ja) 1998-02-06 1999-08-24 Sumitomo Pharmaceut Co Ltd タンドスピロン経皮剤
JPH11228454A (ja) * 1998-02-17 1999-08-24 Sumitomo Chem Co Ltd アルキニル置換アリールブロミド類の製造方法
JP2002020291A (ja) 2000-06-30 2002-01-23 Sumitomo Pharmaceut Co Ltd 認知機能障害の治療剤
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
JPWO2005117886A1 (ja) 2004-06-01 2008-04-03 久光製薬株式会社 貼付剤
ATE413166T1 (de) 2004-11-22 2008-11-15 Hisamitsu Pharmaceutical Co Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff
JP4873871B2 (ja) 2005-02-28 2012-02-08 久光製薬株式会社 粘着剤及び貼付剤
JP5243254B2 (ja) 2006-10-11 2013-07-24 久光製薬株式会社 結晶含有貼付剤
CA2839350A1 (en) 2011-07-05 2013-01-10 Contera Pharma Aps The use of serotonin receptor agonists for treatment of movement disorders
CN104411301B (zh) 2012-04-18 2018-02-06 康特拉医药公司 适于改善运动障碍治疗的口服药物配方
KR20210107729A (ko) * 2018-12-20 2021-09-01 콘테라 파르마 에이/에스 운동 장애의 치료
JP2020145967A (ja) 2019-03-13 2020-09-17 日清食品ホールディングス株式会社 プライマー及び特定昆虫の検出方法
US10758535B1 (en) 2019-04-26 2020-09-01 Sumitomo Dainippon Pharma Co., Ltd. Therapeutic drug for dyskinesia
WO2021166987A1 (ja) 2020-02-19 2021-08-26 大日本住友製薬株式会社 経皮吸収製剤
CN116113402A (zh) * 2020-08-31 2023-05-12 住友制药株式会社 帕金森病的运动并发症治疗药

Also Published As

Publication number Publication date
WO2022045336A1 (ja) 2022-03-03
EP4218764A1 (en) 2023-08-02
US11628169B2 (en) 2023-04-18
KR20230058615A (ko) 2023-05-03
TW202227080A (zh) 2022-07-16
JPWO2022045336A1 (https=) 2022-03-03
CA3189670A1 (en) 2022-03-03
EP4218764A4 (en) 2024-10-02
US20220062282A1 (en) 2022-03-03
AU2021332775A9 (en) 2024-09-26
MX2023002422A (es) 2023-03-22
US20230241062A1 (en) 2023-08-03
AU2021332775A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
EP3459535B1 (en) New therapeutic approaches for treating cmt and related disorders
CN101772346A (zh) 用于降低治疗副作用的方法和组合物
JP2025072496A (ja) ジスキネジア治療薬
AU2007259256A1 (en) Combination preparations comprising bifeprunox and L-DOPA
CN116113402A (zh) 帕金森病的运动并发症治疗药
US7915262B2 (en) Combination preparations comprising SLV308 and a dopamine agonist
US11559525B2 (en) Therapeutic drug for dyskinesia
EA046505B1 (ru) Терапевтическое лекарственное средство для лечения дискинезии
HK40090253A (en) Therapeutic agent for motor complications in parkinson's disease
WO2007144421A1 (en) Combination preparations comprising slv308 and a l-dopa
US8106056B2 (en) Combination preparations comprising bifeprunox and a dopamine agonist
WO2026092738A1 (zh) 一种递送药物的方法及组合物
JP2020033322A (ja) パーキンソン病の治療のための医薬組成物
SA07280316B1 (ar) مستحضرات توليفية تشتمل على bifeprunox وL – DOPA

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination